Immuno-Biological Laboratories Co., Ltd.
Notice: Notice regarding the termination of testing services
Testing services “LipoSEARCH,” “LipoTEST,” and “LipoCULTURE” will be terminated for orders received by March 31, 2027. New orders will be halted from April 2027 onward, with termination upon completion. The impact on consolidated results for the March 2027 term is expected to be minor.
Key Figures
- Number of affected services: 3 (LipoSEARCH, LipoTEST, LipoCULTURE)
- End date: New orders stopped from April 1, 2027; termination upon completion
- Ongoing services: In vitro testing contract service using PX B-cells LA will continue
AI要約
Performance and business overview
A plan to discontinue part of the testing services, which had been focused on drug discovery and research support in the lifestyle-related disease field, was announced by the board. The targets for discontinuation are LipoSEARCH, LipoTEST, and LipoCULTURE, with orders accepted through March 31, 2027. Further orders will be halted. In October 2024, the Akita Clinical Testing Center was closed and integrated into the Fujioka Research Institute, and considering these cost and price level increases, the company plans to focus resources on contract testing services using its in-house ELISA kits. Note that the in vitro testing contract service using PX B-cells LA will continue to be provided after March 31, 2027.
Outlook and impact
The impact on the consolidated results for the March 2027 term is expected to be minor. If any further matters to be disclosed arise in the future, the company states it will promptly disclose them.
Immuno-Biological Laboratories Co., Ltd.
Company overview · Stock price · Financial data · All IR
